SEE HOW RINVOQ
PUTS UC IN CHECK.
AND KEEPS IT THERE.
Achieved clinical remission* at Week 8
Achieved clinical remission* at Week 52
Recommended Maintenance Dosing:
A dose of 30 mg once daily may be considered for patients with refractory, severe or extensive disease. Discontinue RINVOQ if therapeutic response is not achieved with the 30 mg dose.
*Clinical remission is defined as stool frequency subscore ≤1 and not greater than baseline, rectal bleeding subscore of 0, and endoscopic subscore ≤1 without friability.
U-ACHIEVE INDUCTION & U-ACCOMPLISH Study Design Intro:1 8-week, double-blind, placebo-controlled Phase 3 clinical studies of 988 patients (473 patients for U-ACHIEVE and 515 patients for U-ACCOMPLISH) with moderately to severely active ulcerative colitis and demonstrated prior treatment failure to oral aminosalicylates, corticosteroids, immunosuppressants, and/or biologic treatment. Patients were randomized to receive either RINVOQ 45 mg or placebo once daily for 8 weeks. The primary endpoint was clinical remission per modified Mayo Score at Week 8.
U-ACHIEVE MAINTENANCE Study Design Intro:1 52-week, double-blind, placebo-controlled Phase 3 clinical study of 746 patients enrolled were randomized to the maintenance study. The primary efficacy analysis population was the first randomized 451 patients. Patients were randomized to receive RINVOQ 15 mg, 30 mg or placebo once daily for up to 52 weeks. The primary endpoint was clinical remission per modified Mayo Score at Week 52.